Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review.
Birgit TerjungRenate SchmelzRobert EhehaltJochen KlausJana KnopSabine SchwindThomas WilkeAndreas StallmachPublished in: Therapeutic advances in gastroenterology (2020)
There was no evidence for safety concerns regarding pregnancy outcomes associated with VDZ therapy. Due to the limited scope of included records, further research is needed to understand the safety profile regarding the use of VDZ during pregnancy.